吡貝地爾

化合物

吡貝地爾INNpiribedil)是一種抗帕金森病藥物和哌嗪衍生物,可作為D2D3受體激動劑。它還具有α2-腎上腺素受體拮抗劑特性。[2][3]

吡貝地爾
臨床資料
AHFS/Drugs.com國際藥品名稱
給藥途徑口服
ATC碼
法律規範狀態
法律規範
  • Rx-only[1]
  • 處方藥(-only)
藥物動力學數據
生物利用度10%(1小時高峰)
血漿蛋白結合率70–80%
藥物代謝廣泛肝
生物半衰期1.7至6.9小時
排泄途徑(68%)和膽管(25%)
識別資訊
  • 2-[4-(benzo[1,3]dioxol-5-ylmethyl)piperazin-1-yl]pyrimidine
CAS號3605-01-4  checkY
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.020.695 編輯維基數據鏈接
化學資訊
化學式C16H18N4O2
摩爾質量298.35 g·mol−1
3D模型(JSmol英語JSmol
  • C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4
  • InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2 ☒N
  • Key:OQDPVLVUJFGPGQ-UHFFFAOYSA-N ☒N

參考資料

編輯
  1. ^ Active substance: piribedil (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020. 
  2. ^ Millan MJ, Cussac D, Milligan G, Carr C, Audinot V, Gobert A, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. The Journal of Pharmacology and Experimental Therapeutics. June 2001, 297 (3): 876–887 [2024-04-05]. PMID 11356907. (原始內容存檔於2019-12-14). 
  3. ^ Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. The Journal of Pharmacology and Experimental Therapeutics. April 2003, 305 (1): 338–346. PMID 12649387. S2CID 29234876. doi:10.1124/jpet.102.046383.